FDA approves Roche's giredestrant combo for advanced breast cancer
The FDA approved giredestrant with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer and authorized the FoundationOne Liquid CDx assay as a companion diagnostic.





